\
&
Contact us
This was 1 year ago
LocationBrussels
There is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The workshop organised by the Community for European Research and Innovation for Security (CERIS) aims at presenting and discussing European research and innovative solutions, as well as further capability needs, relevant for security in fighting illicit trafficking and criminal activities in the flow of goods and services across the external borders of the European Union, including the security of e-commerce, financial transactions, and/or the circumvention of sanctions.
Interested audience include practitioners, especially customs and law enforcement authorities, but also innovators and policy makers on capabilities such as those related to detection of threats in the flow of goods and services, and risk assessment. The Workshop will bring together updates and EU-funded projects of innovative European technologies in this field, from big data analysis to advanced and safe detection technologies that minimise the disruption to trade flows; present experiences and opportunities of collaborative research and innovation in Europe; and discuss how research results can be more efficiently exploited.
Please find the agenda of the event attached. Registrations are requested via this link.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.